Induction of CDX2 as a differentiation therapy in colorectal cancers
RNA-seq (gene expression) · human · 57 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Colorectal cancerThis series is part of our curated briefing on it.
- Samples
- 57 samples: 53 distinct titles, 2 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- CANDiT: A machine learning framework for differentiation therapy in colorectal cancerCell reports. Medicine · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE237626_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA996052 and SRA study SRP456658. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 20 samples read as cases, 29 as controls.
How we read this: Read from 57 sample titles: 53 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7634891 H14-colon_S22_L001
- GSM7634892 H14-colon_S29_L002
- GSM7634893 PDM2_control_S64_L001
- GSM7634894 PDM2_control_S75_L002
- GSM7634895 PDM5_control_S65_L001
- GSM7634896 PDM5_control_S76_L002
- GSM7634897 PDM50_control_S77_L002
- GSM7634898 PDM50_control_S66_L001
- GSM7634899 PDM95_control_S78_L002
- GSM7634900 PDM95_control_S67_L001
- GSM7634901 PDM185_control_S79_L002
- GSM7634902 PDM277_control_S80_L002
- GSM7634903 PDM359_control_S68_L001
- GSM7634904 PDM359_control_S81_L002
- GSM7634905 PDM363_control_S69_L001
- GSM7634906 PDM363_control_S82_L002
- GSM7634907 H14_control_S70_L001
- GSM7634908 H14_control_S83_L002
- GSM7634909 H17_control_S84_L002
- GSM7634910 H17_control_S71_L001
- GSM7634911 H20_control_S85_L002
- GSM7634912 H20_control_S72_L001
- GSM7634913 PDM2_PF_treated_S86_L002
- GSM7634914 PDM5_PF_treated_S87_L002
- GSM7634915 PDM5_PF_treated_S73_L001
- GSM7634916 PDM50_PF_treated_S74_L001
- GSM7634917 PDM50_PF_treated_S88_L002
- GSM7634918 PDM95_PF_treated_S89_L002
- GSM7634919 PDM95_PF_treated_S75_L001
- GSM7634920 PDM185_PF_treated_S90_L002
- GSM7634921 PDM277_PF_treated_S76_L001
- GSM7634922 PDM277_PF_treated_S91_L002
- GSM7634923 PDM359_PF_treated_S92_L002
- GSM7634924 PDM363_PF_treated_S93_L002
- GSM7634925 H14_PF_treated_S77_L001
- GSM7634926 H14_PF_treated_S94_L002
- GSM7634927 H17_PF_treated_S95_L002
- GSM7634928 H17_PF_treated_S78_L001
- GSM7634929 H20_PF_treated_S96_L002
- GSM7634930 HCT116_DMSO_A1_S25
+ 17 more — browse all 57 samples with per-sample file links →
- GSE250000 Bulk RNA-sequencing of transduced colorectal cancer cell line HCT-116 and breast cancer cell line MCF-7 overexpressing full-lenght p53β or p53β-stop-lost. 4 samples same disease briefing · shares colorectal
- GSE12032 Inherent gene signature of stage II and III colorectal cancer leads in individual recurrence 198 samples same disease briefing · shares colorectal
- GSE109308 Single-cell transcriptomic survey of adenomatous polyposis patients with germline APC mutations 97 samples same disease briefing
- GSE110009 Single cell transcriptome landscape of primary and metastatic tumor in colon cancer 76 samples same disease briefing
- GSE262796 Gene expression changes associated with acquired resistance to anti-EGFR therapy (cetuximab) in colorectal cancer cells 18 samples shares colorectal, therapy
- GSE271689 Enhancing Immunotherapy Outcomes: Spatial Multi-Omics Predictive Models for Non-Small Cell Lung Cancer 586 samples shares therapy
- GSE235090 Pre-existing skin-resident CD8 and γδ T cell circuits mediate immune response in Merkel cell carcinoma and Predict immunotherapy efficacy [scRNA_tissue] 192 samples shares therapy
- GSE289582 Baseline tumor features and peripheral blood immune dynamics that underlie efficacy in MSS metastatic colorectal cancer treated with regorafenib, ipilimumab, and nivolumab [Blood] 115 samples shares colorectal
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.